DOCSLIB.ORG

Index Stahl's Illustrated

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Index Stahl's Illustrated Cambridge University Press 978-0-521-75852-9 - Antidepressants Stahl’s Illustrated Index More information Stahl’s Illustrated Index abbreviations/symbols, 166 psychotherapy, 112, 163 adrenergic autoreceptors, 20, 21 transcranial magnetic stimulation (TMS), affective expression, 34, 153–154 111, 121, 166 affect-meter, 34, 153 vagus nerve stimulation (VNS), 42, 73, agomelatine, 125 85, 98, 111, 120. 166 algorithms, symptom-based, 143, 154–162 antidepressants. see individual drugs alpha 2 antagonists anxiety disorder treatment asenapine, 86 atypical antipsychotics, 123 clozapine, 86 escitalopram, 59 mechanisms of action, 87 paroxetine, 52, 53 mianserin, 86 venlafaxine, 63 mirtazapine, 83, 85, 86, 88–89 anxiolytics, 54 paliperidone, 86 apathy, 37 perospirone, 86 appetite change, 38 quetiapine, 86 appetite suppressants, 106 risperidone, 86 aripiprazole, 123, 128, 162 as second-line treatment, 85–89 asenapine, 86 alpha 2 receptors, 20–26 atomoxetine, 78, 148 alprazolam, 149 atorvastatin, 149 amino acids, 14 attention deficit hyperactivity disorder (ADHD), 7, 78–79 amygdala (A), 38, 39, 166 atypical antipsychotics, 48, 86, 123 ancillary treatment augmentation therapies deep brain stimulation (DBS), 111, 120-121, 166 atypical antipsychotics, 123 cognitive behavioral therapy (CBT), 42, evidence-based, 160 73, 85, 98, 161 with other treatment strategies, 85 electroconvulsive therapy (ECT), 42, 73, symptom-based treatment, 162 85, 98, 112, 161 with TMM, 111–112 interpersonal therapy (IPT), 42, 73, 85, “Z-drugs,” 122 98, 112, 161 Antidepressants: Index 175 © in this web service Cambridge University Press www.cambridge.org Cambridge University Press 978-0-521-75852-9 - Antidepressants Stahl’s Illustrated Index More information basal forebrain, 36, 166 dendritic spine formation, 134 benzodiazepines (BZ), 42, 73, 85 depression. see also major depressive bipolar disorder, 5, 6, 48–49, 113, 123 disorder (MDD) brain. see also specific brain regions overview, 3–12 activity, 39 dysthymia, 2–5 DBS, 111, 120–121, 166 psychotic/delusional, 54 dopaminergic projections, 33 treatment-resistant, 80–81 noradrenergic projections, 23 unipolar depression, 5, 113, 123, 128 regions, 35 symptoms serotonergic projections, 18 affective expression, 153 TMS, 111, 121, 166 inefficient/dysfunctional, 36 VNS, 42, 73, 85, 98, 111, 120, 166 negative affect, 34 brainstem positive affect, 34 locus coeruleus, 23, 24, 86, 120 vasomotor, 129, 136–142 neurotransmitter centers, 33, 35 depression pharmacy, 42, 73, 85, 98 bulimia nervosa, 49 desvenlafaxine, 64–65 bupropion, 50, 76–77 diabetic peripheral neuropathy (DPNP), buspirone, 112, 149, 160 66–67 Diagnostic and Statistical Manual, version IV (DSM-IV), 35 cardiac impairment, 41 disinhibitors, 48, 86, 87, 88, 101 cardiac risk factors. see individual drugs DOPA decarboxylase (DDC), 19, 27 catechol-O-methyl-transferase (COMT), 19, 27 dopamine (DA) children/adolescents: drug dosing/ defined, 166 interactions. see individual drugs deficiency, 8–9 chronic pain, 7, 66, 67, 68, 69 dysfunction, 36 citalopram, 56–57 5HT interaction, 31 clozapine, 86 5HT/NE interaction, 32 codeine, 148 neurons, 19 cognitive therapy, 161 partial agonists, 42, 73, 85 combination treatment, 143 pathways, 33, 153 cytochrome P450 enzyme system (CYP450) projections, 37 defined, 166 receptors, 28 CYP450 1A2, 47, 145, 147 synthesis/metabolism, 27 CYP450 2C19, 145 transporters, 28, 74, 166 CYP450 2C9, 145 as a trimonoamine, 114–116 CYP450 2D6, 47, 145, 146, 148 dopamine beta hydroxylase (DBH), 19 CYP450 3A4, 47, 145, 149 dopamine partial agonists (DPAs), 42, 73, 85 decarboxylase (AADC), 14 dopamine transporters (DATs), 28, 74, 166 decongestants, 106 “dopamine-deficiency syndrome,” 76 deep brain stimulation (DBS), 111, dopaminergic neurotransmission, 28, 29, 120–121, 166 153 176 Stahl’s Illustrated © in this web service Cambridge University Press www.cambridge.org Cambridge University Press 978-0-521-75852-9 - Antidepressants Stahl’s Illustrated Index More information dorsolateral prefrontal cortex (DLPFC), 37, gamma aminobutyric (GABA) interneurons, 39, 166 31, 32, 134 drug metabolism, 144 generalized anxiety disorder, 122 drugs: dosing/interactions. see individual genes drugs expression, 12, 135 duloxetine, 66–69, 147–148 polymorphism, 146 dysthymia risk genes, 40 defined, 3 genetic polymorphism, 146 clinical trials, 150 gut symptom chart, 4, 5 CYP450 enzyme system, 144 MAO-A presence in, 109–110 electroconvulsive therapy (ECT), 42, 73, 85, 98, 112, 161 hepatic risk factors. see individual drugs enzymes, 14, 19, 27. see also cytochrome hippocampus (H), 166 P450 enzyme system (CYP450) erythomycin, 149 hormones escitalopram, 58–59 estradiol, 131, 133, 134, 135 estradiol (E2), 131, 133, 134, 135 estrogen, 129, 130–142 estrogen progesterone, 133 for depression, 140 testosterone, 112, 130 estrogen replacement therapy (ERT), 131 thyroid hormone, 42, 73, 85, 111, 115, health risks, 137, 140 137 level fluctuation, 129, 133, 138, 142 human neurokinins, 126–127 in menstrual cycle, 134 hypertensive crisis, 106–107 receptors, 135 hyperthermia, 106 vasomotor symptoms and, 138, 139 hyperthymic temperament, 3 eszopiclone, 122 hypnotic drugs, 122 euthymia, 2 hypomania, 2, 4, 5, 150 executive dysfunction, 37 hypothalamic thermoregulatory centers, 137–139 5HT. see serotonin (5HT) hypothalamus (Hy), 23, 35, 36, 137–139, 5-hydroxy-tryptophan (5HTP), 14 166 5-L-methyl-tetrahydrofolate (MTHF)see L-methylfolate. insomnia, 122 fatigue, 37 interpersonal therapy (IPT), 42, 73, 85, 98, feelings, 38 161 “fibrofog,” 69 fibromyalgia, 63, 66–69 ketoconazole, 149 fluoxetine, 48–49, 148, 149 fluvoxamine, 54–55, 147, 149 lithium (Li), 111, 113, 114, 137, 166 folic acid, 119 L-methylfolate, 111, 116–119, 137, 162, food, tyramine content, 107–108 166 locus coeruleus, 24, 86, 120 lovastatin, 149 Antidepressants: Index 177 © in this web service Cambridge University Press www.cambridge.org Cambridge University Press 978-0-521-75852-9 - Antidepressants Stahl’s Illustrated Index More information major depressive disorder (MDD). see also hypothesis of antidepressant action, 9, depression 11–12 comorbidities of, 7 hypothesis of depression, 8–10 relapse, 152 receptors, 10–11 remission, 122, 151 transporters, 9 risk genes, 40 monoamine oxidase inhibitors (MAOIs) symptom-based treatment algorithms, defined, 166 143, 154–162 drugs to avoid, 106 symptoms, 35, 156–159 food monitoring, 107–108 therapeutic interventions, 112 hypertensive crisis, 106–107 treatment drugs interaction with SRIs, 105 atomoxetine, 78, 148 MAO-A/MAO-B, 14, 19, 27, 104–105, atypical antipsychotics, 123 110 bupropion, 77 as second-line treatment, 104–110 citalopram, 56-57 selegiline (transdermal) and, 110 desvenlafaxine, 65 tyramine and, 107–110 duloxetine, 66–67 monotherapies escitalopram, 59 for affective disorder, 154 fluoxetine, 48–49, 149 augmentation, 80, 111, 160, 162 fluvoxamine, 149 first-line, 42, 73, 85, 123, 160 MAOIs, 98, 104-110 second-line, 73, 85, 90–95, 98, 161 milnacipran, 68–69 third-line, 98 mirtazapine, 89 in treatment plans, 111 nefazodone, 95, 149 mood chart, 2 paroxetine, 53 mood disorders. see also bipolar disorder; reboxetine, 80–81 major depressive disorder (MDD) sertraline, 50–51, 54 arousal and cognition, 18, 23 trazodone, 83, 85, 90, 92-93 identifying, 4 venlafaxine, 62-63, 148 mood chart, 2 TCAs, 98-103 mood-related symptoms, 153 men, depression and, 130 as progressive, 6 menopause, 129, 140–142 muscarinic/cholinergic antagonism (m-ACh), menstrual cycle, 133 47 mianserin, 86 milnacipran, 68–69, 147 nefazodone, 83, 85, 90, 94–95, 149 mirtazapine, 83, 85, 88–89 negative affect, 34, 153, 154 modafinil, 162 neurokinins, 126–127 monoamine. see also dopamine (DA); neuromodulation, 120–121 neurotransmitters; norepinephrine (NE); neuronal circuits, 17 serotonin (5HT) neurotransmitters 33, 35 8, 9, 10, 166 overview, 8–12 new treatments, 124–128 deficiency, 8–9, 140 nicotine addiction, 76–77 nitric oxide synthetase (NOS), 47, 166 178 Stahl’s Illustrated © in this web service Cambridge University Press www.cambridge.org Cambridge University Press 978-0-521-75852-9 - Antidepressants Stahl’s Illustrated Index More information N-methyl-d-aspartate (NMDA) receptors, 134 perimenopause, 136–142 nonremitters, 151 perospirone, 86 noradrenergic dysfunction, 34, 86, 153 pharmacokinetics, 143–149 norepinephrine (NE) pimozide, 149 defined, 166 positive affect, 34, 153, 154 affects of, 18 postmenopausal depression, 140–142 DA/5HT interaction, 32 postpartum depression, 131 deficiency, 8–9 posttraumatic stress disorder, 53 dysfunction, 36 prefrontal cortex (PFC), 36, 60–61, 75, 166 5HT interaction, 24, 25 pregnancy risk factors, 132. see also neurons, 19 individual drugs pathways, 22 premenstrual dysphoric disorder (PMDD), 49, projections, 37 51, 53 receptors, 20–22 presynaptic receptors, 20–21, 28–30 transporters, 19, 20, 74, 166 progesterone, 133 as a trimonoamine, 114–116 protease inhibitors, 149 norepinephrine dopamine dishinhibitors psychomotor agitation, 36 (NDDIs), 48, 88, 125, 166 psychotherapy, 112, 163 norepinephrine dopamine reuptake inhibitors puberty, 131 (NDRIs) defined, 166 quetiapine, 86, 123, 128 drugs atomoxetine, 78–79, 148 radafaxine, 74 bupropion, 76–77 rate-limiting enzymes, 14, 19, 27 radafaxine, 74 reboxetine, 80–81 reboxetine, 80–81 remission, 143, 151 as first-line treatment, 71, 73, 160 renal risk factors. see individual drugs molecular action, 74 retardation, 36 regional effects, 75 reuptake pumps, 9, 11 norepinephrine reuptake pump, 19 reversible MAOs (RIMAs), 109 norquetiapine, 123 risperidone,
Load more

Recommended publications
  • FROM the LITERATURE PET in Assessment of Abuse Potential
    NEWSLINE FROM THE LITERATURE Each month the editor of Newsline drug radafaxine ([2S,3S])-2-[3-chlo- in the putamen. The authors con- selects articles on diagnostic, thera- rophenyl]-3,5,5,-trimethyl-2-mor- cluded that these and other data “sug- peutic, research, and practice issues pholinol hydrochloride). Radafaxine gest that the neurodegenerative from a range of international publica- is a potent metabolite of bupropion process in PD follows a negative ex- tions. Most selections come from out- that is being evaluated both as a treat- ponential course and slows down side the standard canon of nuclear ment for depression and for possible with increasing symptom duration, medicine and radiology journals. Note use in treatment of obesity. The study contradicting the long-latency hypo- that although we have divided the ar- included 8 healthy men who under- thesis of PD.” ticles into diagnostic and therapeutic went 11C-cocaine PET imaging at 1, Archives of Neurology categories, these lines are increasingly 4, 8, and 24 hours after radafaxine blurred as nuclear medicine capabili- administration. The authors found ties rapidly expand. Many diagnostic that DAT blockade by radafaxine PET and rCBF in Cocaine capabilities are now enlisted in direct was slow, reaching 11% at 1 hour Use Disorder support of and, often, in real-time con- and a peak blockade of 22% at 4 In an article e-published ahead of junction with, therapies. These briefs hours. The maximum blockade in print in the March 9 issue of the are offered as a monthly window on the any single subject was 33%.
    [Show full text]
  • Compositions and Methods for Selective Delivery of Oligonucleotide Molecules to Specific Neuron Types
    (19) TZZ ¥Z_T (11) EP 2 380 595 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 26.10.2011 Bulletin 2011/43 A61K 47/48 (2006.01) C12N 15/11 (2006.01) A61P 25/00 (2006.01) A61K 49/00 (2006.01) (2006.01) (21) Application number: 10382087.4 A61K 51/00 (22) Date of filing: 19.04.2010 (84) Designated Contracting States: • Alvarado Urbina, Gabriel AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Nepean Ontario K2G 4Z1 (CA) HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL • Bortolozzi Biassoni, Analia Alejandra PT RO SE SI SK SM TR E-08036, Barcelona (ES) Designated Extension States: • Artigas Perez, Francesc AL BA ME RS E-08036, Barcelona (ES) • Vila Bover, Miquel (71) Applicant: Nlife Therapeutics S.L. 15006 La Coruna (ES) E-08035, Barcelona (ES) (72) Inventors: (74) Representative: ABG Patentes, S.L. • Montefeltro, Andrés Pablo Avenida de Burgos 16D E-08014, Barcelon (ES) Edificio Euromor 28036 Madrid (ES) (54) Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types (57) The invention provides a conjugate comprising nucleuc acid toi cell of interests and thus, for the treat- (i) a nucleic acid which is complementary to a target nu- ment of diseases which require a down-regulation of the cleic acid sequence and which expression prevents or protein encoded by the target nucleic acid as well as for reduces expression of the target nucleic acid and (ii) a the delivery of contrast agents to the cells for diagnostic selectivity agent which is capable of binding with high purposes.
    [Show full text]
  • Phenylmorpholines and Analogues Thereof Phenylmorpholine Und Analoge Davon Phenylmorpholines Et Analogues De Celles-Ci
    (19) TZZ __T (11) EP 2 571 858 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07D 265/30 (2006.01) A61K 31/5375 (2006.01) 20.06.2018 Bulletin 2018/25 A61P 25/24 (2006.01) A61P 25/16 (2006.01) A61P 25/18 (2006.01) (21) Application number: 11723158.9 (86) International application number: (22) Date of filing: 20.05.2011 PCT/US2011/037361 (87) International publication number: WO 2011/146850 (24.11.2011 Gazette 2011/47) (54) PHENYLMORPHOLINES AND ANALOGUES THEREOF PHENYLMORPHOLINE UND ANALOGE DAVON PHENYLMORPHOLINES ET ANALOGUES DE CELLES-CI (84) Designated Contracting States: • DECKER, Ann Marie AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Durham, North Carolina 27713 (US) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR (74) Representative: Hoeger, Stellrecht & Partner Patentanwälte mbB (30) Priority: 21.05.2010 US 347259 P Uhlandstrasse 14c 70182 Stuttgart (DE) (43) Date of publication of application: 27.03.2013 Bulletin 2013/13 (56) References cited: WO-A1-2004/052372 WO-A1-2008/026046 (73) Proprietors: WO-A1-2008/087512 DE-B- 1 135 464 • Research Triangle Institute FR-A- 1 397 563 GB-A- 883 220 Research Triangle Park, North Carolina 27709 GB-A- 899 386 US-A1- 2005 267 096 (US) • United States of America, as represented by • R.A. GLENNON ET AL.: "Beta-Oxygenated The Secretary, Department of Health and Human Analogues of the 5-HT2A Serotonin Receptor Services Agonist Bethesda, Maryland 20892-7660 (US) 1-(4-Bromo-2,5-dimethoxyphenyl)-2-aminopro pane", JOURNAL OF MEDICINAL CHEMISTRY, (72) Inventors: vol.
    [Show full text]
  • Modifications to the Harmonized Tariff Schedule of the United States To
    U.S. International Trade Commission COMMISSIONERS Shara L. Aranoff, Chairman Daniel R. Pearson, Vice Chairman Deanna Tanner Okun Charlotte R. Lane Irving A. Williamson Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement the Dominican Republic- Central America-United States Free Trade Agreement With Respect to Costa Rica Publication 4038 December 2008 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 18, 2008, set forth in the Appendix hereto, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement the Dominican Republic- Central America-United States Free Trade Agreement, as approved in the Dominican Republic-Central America- United States Free Trade Agreement Implementation Act, with respect to Costa Rica. (This page is intentionally blank) Annex I Effective with respect to goods that are entered, or withdrawn from warehouse for consumption, on or after January 1, 2009, the Harmonized Tariff Schedule of the United States (HTS) is modified as provided herein, with bracketed matter included to assist in the understanding of proclaimed modifications. The following supersedes matter now in the HTS. (1). General note 4 is modified as follows: (a). by deleting from subdivision (a) the following country from the enumeration of independent beneficiary developing countries: Costa Rica (b).
    [Show full text]
  • The Slow and Long-Lasting Blockade of Dopamine Transporters in Human Brain Induced by the New Antidepressant Drug Radafaxine Predict Poor Reinforcing Effects Nora D
    The Slow and Long-Lasting Blockade of Dopamine Transporters in Human Brain Induced by the New Antidepressant Drug Radafaxine Predict Poor Reinforcing Effects Nora D. Volkow, Gene-Jack Wang, Joanna S. Fowler, Susan Learned-Coughlin, Julia Yang, Jean Logan, David Schlyer, John S. Gatley, Christopher Wong, Wei Zhu, Naomi Pappas, Michael Schueller, Millard Jayne, Pauline Carter, Donald Warner, Yu-Shin Ding, Colleen Shea, and Youwen Xu Background: (2S,3S)-2-(3-Chlorophenyl)-3,5,5,-trimethyl-2-morpholinol hydrochloride (radafaxine) is a new antidepressant that blocks dopamine transporters (DAT). A concern with drugs that block (DAT) is their potential reinforcing effects and abuse liability. Using positron emission tomography (PET) we have shown that for DAT-blocking drugs to produce reinforcing effects they must induce Ͼ50% DAT blockade and the blockade has to be fast (within 15 minutes). This study measures the potency and kinetics for DAT blockade by radafaxine in human brain. Methods: PET and [ 11C]cocaine were used to estimate DAT blockade at 1, 4, 8, and 24 hours after radafaxine (40 mg p.o) in 8 controls. Plasma pharmacokinetics and behavioral and cardiovascular effects were measured in parallel. Results: DAT blockade by radafaxine was slow, and at 1 hour, it was 11%. Peak blockade occurred at about 4 hours and was 22%. Blockade was long lasting: at 8 hours 17%, and at 24 hours 15%. Peak plasma concentration occurred about 4 to 8 hours. No behavioral or cardiovascular effects were observed. Conclusions: The relatively low potency of radafaxine in blocking DAT and its slow blockade suggests that it is unlikely to have reinforcing effects.
    [Show full text]
  • I Regulations
    23.2.2007 EN Official Journal of the European Union L 56/1 I (Acts adopted under the EC Treaty/Euratom Treaty whose publication is obligatory) REGULATIONS COUNCIL REGULATION (EC) No 129/2007 of 12 February 2007 providing for duty-free treatment for specified pharmaceutical active ingredients bearing an ‘international non-proprietary name’ (INN) from the World Health Organisation and specified products used for the manufacture of finished pharmaceuticals and amending Annex I to Regulation (EEC) No 2658/87 THE COUNCIL OF THE EUROPEAN UNION, (4) In the course of three such reviews it was concluded that a certain number of additional INNs and intermediates used for production and manufacture of finished pharmaceu- ticals should be granted duty-free treatment, that certain of Having regard to the Treaty establishing the European Commu- these intermediates should be transferred to the list of INNs, nity, and in particular Article 133 thereof, and that the list of specified prefixes and suffixes for salts, esters or hydrates of INNs should be expanded. Having regard to the proposal from the Commission, (5) Council Regulation (EEC) No 2658/87 of 23 July 1987 on the tariff and statistical nomenclature and on the Common Customs Tariff (1) established the Combined Nomenclature Whereas: (CN) and set out the conventional duty rates of the Common Customs Tariff. (1) In the course of the Uruguay Round negotiations, the Community and a number of countries agreed that duty- (6) Regulation (EEC) No 2658/87 should therefore be amended free treatment should be granted to pharmaceutical accordingly, products falling within the Harmonised System (HS) Chapter 30 and HS headings 2936, 2937, 2939 and 2941 as well as to designated pharmaceutical active HAS ADOPTED THIS REGULATION: ingredients bearing an ‘international non-proprietary name’ (INN) from the World Health Organisation, specified salts, esters or hydrates of such INNs, and designated inter- Article 1 mediates used for the production and manufacture of finished products.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr
    US008158152B2 (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr. 17, 2012 (54) LYOPHILIZATION PROCESS AND 6,884,422 B1 4/2005 Liu et al. PRODUCTS OBTANED THEREBY 6,900, 184 B2 5/2005 Cohen et al. 2002fOO 10357 A1 1/2002 Stogniew etal. 2002/009 1270 A1 7, 2002 Wu et al. (75) Inventor: Nageswara R. Palepu. Mill Creek, WA 2002/0143038 A1 10/2002 Bandyopadhyay et al. (US) 2002fO155097 A1 10, 2002 Te 2003, OO68416 A1 4/2003 Burgess et al. 2003/0077321 A1 4/2003 Kiel et al. (73) Assignee: SciDose LLC, Amherst, MA (US) 2003, OO82236 A1 5/2003 Mathiowitz et al. 2003/0096378 A1 5/2003 Qiu et al. (*) Notice: Subject to any disclaimer, the term of this 2003/OO96797 A1 5/2003 Stogniew et al. patent is extended or adjusted under 35 2003.01.1331.6 A1 6/2003 Kaisheva et al. U.S.C. 154(b) by 1560 days. 2003. O191157 A1 10, 2003 Doen 2003/0202978 A1 10, 2003 Maa et al. 2003/0211042 A1 11/2003 Evans (21) Appl. No.: 11/282,507 2003/0229027 A1 12/2003 Eissens et al. 2004.0005351 A1 1/2004 Kwon (22) Filed: Nov. 18, 2005 2004/0042971 A1 3/2004 Truong-Le et al. 2004/0042972 A1 3/2004 Truong-Le et al. (65) Prior Publication Data 2004.0043042 A1 3/2004 Johnson et al. 2004/OO57927 A1 3/2004 Warne et al. US 2007/O116729 A1 May 24, 2007 2004, OO63792 A1 4/2004 Khera et al.
    [Show full text]
  • Comparison of In-Vitro Stereoselective Metabolism of Bupropion in Human, Monkey, Rat and Mouse Liver Microsomes
    Comparison of in-vitro stereoselective metabolism of bupropion in human, monkey, rat and mouse liver microsomes Chandrali Bhattacharya, Danielle Kirby, Michael Van Stipdonk, Robert E. Stratford 1. Introduction Bupropion has been marketed as Wellbutrin® and Zyban® for the management of depression and as a smoking cessation aid, respectively, since the early 1990s [1]. Its recent approval by the U.S. FDA in combination with naltrexone, Contrave®, for obesity, and a recent positive outcome in clinical trials for attention-deficit/hyperactivity disorder (ADHD), further exemplify the multifaceted therapeutic potential of this drug [2-6]. However, despite being a biopharmaceutical classification system (BCS) class I drug, failure of generic bupropion to meet U.S. FDA bioequivalence standards has drawn attention to the problem of interpatient variability in its clinical response [7-15]. This is of concern due to its high propensity to induce seizures and other side effects [7, 10, 11, 16-19]. With over 40 million patients worldwide prescribed bupropion [1], understanding causes of inter-subject variability is critical. Variability regarding bupropion metabolism is considered chiefly responsible for variability in its response [10, 12-14, 20-22]. The disposition and pharmacology of bupropion are complex, since both bupropion and its metabolites have diverse pharmacokinetic and pharmacodynamic profiles [20-30]. Though bupropion is clinically administered as a racemate, plasma exposure of R-bupropion and its metabolites are reported to be higher than exposure to the S enantiomer and its metabolites [20-22]. Both enantiomers are reported to undergo stereoselective phase I and II metabolism mediated by multiple enzymes [20, 23, 28]. In-vitro and in-vivo studies indicate stereoselective phase I and II metabolic pathways contribute to observed differences in ___________________________________________________________________plasma profiles of bupropion enantiomers and their metabolites [20-23].
    [Show full text]
  • Tools for Optimising Pharmacotherapy in Psychiatry (Therapeutic Drug Monitoring, Molecular Brain Imaging and Pharmacogenetic Tests) Focus on Antidepressants Eap, C
    University of Southern Denmark Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests) focus on antidepressants Eap, C. B.; Gründer, G.; Baumann, P.; Ansermot, N.; Conca, A.; Corruble, E.; Crettol, S.; Dahl, M. L.; de Leon, J.; Greiner, C.; Howes, O.; Kim, E.; Lanzenberger, R.; Meyer, J. H.; Moessner, R.; Mulder, H.; Müller, D. J.; Reis, M.; Riederer, P.; Ruhe, H. G.; Spigset, O.; Spina, E.; Stegman, B.; Steimer, W.; Stingl, J.; Suzen, S.; Uchida, H.; Unterecker, S.; Vandenberghe, F.; Hiemke, C. Published in: World Journal of Biological Psychiatry DOI: 10.1080/15622975.2021.1878427 Publication date: 2021 Document version: Final published version Document license: CC BY-NC-ND Citation for pulished version (APA): Eap, C. B., Gründer, G., Baumann, P., Ansermot, N., Conca, A., Corruble, E., Crettol, S., Dahl, M. L., de Leon, J., Greiner, C., Howes, O., Kim, E., Lanzenberger, R., Meyer, J. H., Moessner, R., Mulder, H., Müller, D. J., Reis, M., Riederer, P., ... Hiemke, C. (2021). Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants. World Journal of Biological Psychiatry. https://doi.org/10.1080/15622975.2021.1878427 Go to publication entry in University of Southern Denmark's Research Portal Terms of use This work is brought to you by the University of Southern Denmark. Unless otherwise specified it has been shared according to the terms for self-archiving. If no other license is stated, these terms apply: • You may download this work for personal use only. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying this open access version If you believe that this document breaches copyright please contact us providing details and we will investigate your claim.
    [Show full text]
  • Canm Guidelines for Imaging of the Dopamine Transport System in Evaluation of Movement Disorders
    CANM GUIDELINES FOR IMAGING OF THE DOPAMINE TRANSPORT SYSTEM IN EVALUATION OF MOVEMENT DISORDERS Photo credit GE Healthcare Document prepared by Drs. Alfonso Fasano, Ruban Gnanakumar, Heather Rigby, Andrew Ross, Jean-Paul Soucy, Alex Tamm January 2020 ABSTRACT In the investigation of movement disorders in which Dopamine transporter loss is a potential component, most commonly Parkinsonism, and when there is diagnostic uncertainty, imaging with 123I-ioflupane can provide important information. It is recommended in the following situations: 1) history or examination features that could be compatible with essential tremor (i.e. PD vs. ET) 2) mild or subtle signs of parkinsonism (i.e. PD vs. normal variant) 3) a history of prolonged exposure to a dopamine receptor blocking agent (i.e. PD vs. drug-induced parkinsonism) 4) distractible or variable features on exam (ie. PD vs. functional parkinsonism) 5) prominent dystonia (i.e. PD vs. dystonic tremor) 6) suspected superimposed parkinsonism (e.g. facial bradykinesia) in persons with a known neurologic disease affecting the motor system (myelopathy, stroke, neuromuscular disease, etc.) 7) other atypical signs (poor response to levodopa, lack of disease progression, very young onset, etc.) The only contraindications include: Absolute: 1. Pregnancy. 2. Inability to cooperate with brain imaging. 3. Known hypersensitivity to the active substance or to any of its excipients. An iodine allergy is not an absolute contraindication. Relative: 1. Breastfeeding. Patient preparation, obtaining history and ensuring the patient is not on interfering agents is vital. Additionally, exam acquisition parameters and patient positioning are an integral component to obtaining a diagnostic exam and should be followed.
    [Show full text]
  • Presidential Green Chemistry Challenge Awards Program
    The Presidential Green Chemistry Challenge Awards Program Summary of 2005 Award Entries and Recipients United States Office of Pollution EPA744-R-05-002 Environmental Protection Prevention and June 2005 Agency Toxics (7406M) www.epa.gov/greenchemistry www.epa.gov/greenchemistry 2 Recycled/Recyclable—Printed with Vegetable Oil Based Inks on 100% Postconsumer, Process Chlorine Free Recycled Paper The Presidential Green Chemistry Challenge Awards Program Contents Summary of 2005 Award Entries and Recipients. 1 Awards. 3 Academic Award . 3 Small Business Award . 4 Alternative Synthetic Pathways Awards. 5 Alternative Solvents/Reaction Conditions Award . 7 Designing Safer Chemicals Award . 8 Entries From Academia . 9 Entries From Small Businesses. 17 Entries From Industry and Government . 33 Index . 53 i The Presidential Green Chemistry Challenge Awards Program Summary of 2005 Award Entries and Recipients The Presidential Green Chemistry Challenge Awards Program is a competitive incentive to create environmentally preferable chemicals and chemical processes. This year EPA cele- brates an important milestone: 10 years of innovative, award-winning technologies developed by high-quality nominees. The national policy established by the 1990 Pollution Prevention Act is aimed at reduc- ing pollution at its source whenever feasible. By applying scientific solutions to real-world environmental problems, the Green Chemistry Challenge has significantly reduced hazards associated with the design, manufacture, and use of chemicals. Through a voluntary EPA Design for the Environment partnership with the chemical industry and professional scientific community, this annual award program seeks to discov- er, highlight, and honor green chemistry. Entries for the 2005 awards were judged by an independent panel of technical experts convened by the American Chemical Society.
    [Show full text]
  • Bupropion ­ Wikipedia
    13/01/2017 Bupropion ­ Wikipedia Bupropion From Wikipedia, the free encyclopedia Bupropion is a medication primarily used as an antidepressant Bupropion and smoking cessation aid.[6][7][8] It is marketed as Wellbutrin and Zyban among other trade names. It is one of the most frequently prescribed antidepressants in the United States and Canada,[9] although in many countries this is an off­label use.[10] It is an effective antidepressant on its own, but is also popular as an add­on medication in cases of incomplete response to first­ line SSRI antidepressants.[11] Bupropion is taken in tablet form and is available only by prescription in most countries.[9] The most important side effect is an increase in risk for epileptic seizures, which caused the drug to be withdrawn from the market for some time and then caused the recommended dosage to be reduced.[11] In comparison to many other antidepressants, it does not cause as much weight gain or sexual dysfunction.[11] Bupropion acts as an norepinephrine­dopamine reuptake inhibitor (NDRI). It is an atypical antidepressant, different from most commonly prescribed antidepressants such as selective 1 : 1 mixture (racemate) serotonin reuptake inhibitors (SSRIs).[10] Clinical data Pronunciation /bjuːˈproʊ.pi.ɒn/ Bupropion is known to affect several different biological bew­ᐟᐣᐝᐏ­pee­on targets.[11][12] It often is described as a norepinephrine­dopamine Trade names Wellbutrin, Elontril, Zyban reuptake inhibitor (NDRI), and is also a nicotinic antagonist.[12][13] However, bupropion does not appear to have AHFS/Drugs.com Monograph (https://www.drugs. significant dopaminergic actions in humans under normal com/monograph/bupropion­hydr clinical circumstances.[12][14] Chemically, bupropion belongs to ochloride.html) the class of aminoketones and is similar in structure to MedlinePlus a695033 (https://medlineplus.go stimulants such as cathinone and amfepramone, and to v/druginfo/meds/a695033.html) [11] phenethylamines in general.
    [Show full text]